Advertisement
Letter to the Editor| Volume 174, P313-314, October 2022

Response to letter entitled: Re: ‘Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial’

  • Author Footnotes
    1 Equal contribution to this article.
    Changying Shi
    Correspondence
    Corresponding author: Department of Hepatology, Eastern Hepatobiliary Surgery Hospital, Affiliated to Second Military Medical University, No.225, Changhai Rd., Shanghai, China.
    Footnotes
    1 Equal contribution to this article.
    Affiliations
    Department of Hepatology, Eastern Hepatobiliary Surgery Hospital, Affiliated to Second Military Medical University, Shanghai, China
    Search for articles by this author
  • Author Footnotes
    1 Equal contribution to this article.
    Yong Li
    Footnotes
    1 Equal contribution to this article.
    Affiliations
    Department of Radiation Oncology, Eastern Hepatobiliary Surgery Hospital, Affiliated to Second Military Medical University, Shanghai, China

    Center of Radiation Oncology, Wujing Hospital, Shanghai, China
    Search for articles by this author
  • Author Footnotes
    1 Equal contribution to this article.
    Li Geng
    Footnotes
    1 Equal contribution to this article.
    Affiliations
    Department of Hepatology, Eastern Hepatobiliary Surgery Hospital, Affiliated to Second Military Medical University, Shanghai, China
    Search for articles by this author
  • Weifeng Shen
    Affiliations
    Department of Hepatology, Eastern Hepatobiliary Surgery Hospital, Affiliated to Second Military Medical University, Shanghai, China
    Search for articles by this author
  • Chengjun Sui
    Affiliations
    Department of Hepatology, Eastern Hepatobiliary Surgery Hospital, Affiliated to Second Military Medical University, Shanghai, China
    Search for articles by this author
  • Binghua Dai
    Affiliations
    Department of Hepatology, Eastern Hepatobiliary Surgery Hospital, Affiliated to Second Military Medical University, Shanghai, China
    Search for articles by this author
  • Jiongjiong Lu
    Affiliations
    Department of Hepatology, Eastern Hepatobiliary Surgery Hospital, Affiliated to Second Military Medical University, Shanghai, China
    Search for articles by this author
  • Mianshun Pan
    Affiliations
    Center of Radiation Oncology, Wujing Hospital, Shanghai, China
    Search for articles by this author
  • Jiamei Yang
    Correspondence
    Corresponding author: Department of Hepatology, Eastern Hepatobiliary Surgery Hospital, Affiliated to Second Military Medical University, No.225, Changhai Rd., Shanghai, China.
    Affiliations
    Department of Hepatology, Eastern Hepatobiliary Surgery Hospital, Affiliated to Second Military Medical University, Shanghai, China
    Search for articles by this author
  • Author Footnotes
    1 Equal contribution to this article.
Published:July 18, 2022DOI:https://doi.org/10.1016/j.ejca.2022.06.022
Response to letter entitled: Re: ‘Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial’
Previous ArticleRe: Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial
Next ArticleRe: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib
      We are writing to respond to Duan et al.’s comments concerning our article titled, ‘Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial.’ We thank these authors for their constructive feedback.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Oguro S.
        • Yoshimoto J.
        • Imamura H.
        • Ishizaki Y.
        • Kawasaki S.
        Clinical significance of macroscopic no-margin hepatectomy for hepatocellular carcinoma.
        HPB (Oxford). 2018 Sep; 20: 872-880https://doi.org/10.1016/j.hpb.2018.03.012
        View in Article
        • Xie D.Y.
        • Ren Z.G.
        • Zhou J.
        • Fan J.
        • Gao Q.
        2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights.
        Hepatobiliary Surg Nutr. 2020 Aug; 9 (PMID: 32832496; PMCID: PMC7423548): 452-463https://doi.org/10.21037/hbsn-20-480
        View in Article
        • Reig M.
        • Forner A.
        • Rimola J.
        • Ferrer-Fàbrega J.
        • Burrel M.
        • Garcia-Criado Á
        • et al.
        BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.
        J Hepatol. 2022 Mar; 76: 681-693https://doi.org/10.1016/j.jhep.2021.11.018
        View in Article
        • Llovet J.M.
        • Kelley R.K.
        • Villanueva A.
        • Singal A.G.
        • Pikarsky E.
        • Roayaie S.
        • et al.
        Hepatocellular carcinoma.
        Nat Rev Dis Prim. 2021 Jan 21; 7: 6https://doi.org/10.1038/s41572-020-00240-3
        View in Article

      Article info

      Publication history

      Published online: July 18, 2022
      Accepted: June 10, 2022
      Received: May 23, 2022

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2022.06.022

      Copyright

      © 2022 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      Linked Article

      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX